Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Therapeutics Ltd.

Enlivex Therapeutics is focused on harnessing macrophages to treat inflammatory diseases through its cell therapy platform Allocetra™, which is designed for various therapeutic applications.

NASDAQ:ENLV

Enlivex Therapeutics

Last Close

1.23

11/11 21:00

Market Cap

29.22M

Beta: 0.61

Volume Today

212.47K

Avg: 34.86K

PE Ratio

−1.87

PFCF: −1.95

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics